Home
NRSN
NRSN News

Latest NeuroSense Therapeutics Ltd. (NRSN) News on May 15, 2025

Why This Nano-Cap Stock Might Skyrocket To $14, Per Analyst Insights

Benzinga

3 days ago

Why This Nano-Cap Stock Might Skyrocket To $14, Per Analyst Insights

NeuroSense Therapeutics Announces Successful Completion of Commercial Manufacturing Scale-Up for PrimeC in Preparation for Potential Canadian Market Launch

PR Newswire

8 days ago

NeuroSense Therapeutics Announces Successful Completion of Commercial Manufacturing Scale-Up for PrimeC in Preparation for Potential Canadian Market Launch

NeuroSense Therapeutics Releases Letter to Shareholders Outlining Clinical Progress, Regulatory Strategy, and Partnership Update

PR Newswire

21 days ago

NeuroSense Therapeutics Releases Letter to Shareholders Outlining Clinical Progress, Regulatory Strategy, and Partnership Update

NeuroSense Therapeutics Announces Transformative Phase 2b MicroRNA Data, Highlighting PrimeC's Promise as a Disease-Modifying ALS Treatment

PR Newswire

a month ago

NeuroSense Therapeutics Announces Transformative Phase 2b MicroRNA Data, Highlighting PrimeC's Promise as a Disease-Modifying ALS Treatment

NeuroSense Therapeutics Reports Year End 2024 Financial Results and Provides Business Updates

PR Newswire

a month ago

NeuroSense Therapeutics Reports Year End 2024 Financial Results and Provides Business Updates

NeuroSense Therapeutics to Present New Data from PrimeC's Phase 2b Trial in ALS at the Annual American Academy of Neurology Meeting

PR Newswire

a month ago

NeuroSense Therapeutics to Present New Data from PrimeC's Phase 2b Trial in ALS at the Annual American Academy of Neurology Meeting

Business Wire

2 months ago

Market Alert: NeuroSense Therapeutics Advances Toward Early Canadian Commercialization of ALS Drug

Business Wire

2 months ago

PESG Releases Report on NeuroSense Therapeutics: Groundbreaking ALS Therapy Signals Massive Potential Opportunity in Billion Dollar Treatment Landscape

MT Newswires

4 months ago

NeuroSense Therapeutics Regains Compliance With Nasdaq Equity Requirement

NeuroSense Regains Compliance with Nasdaq's Minimum Equity Requirement

PR Newswire

4 months ago

NeuroSense Regains Compliance with Nasdaq's Minimum Equity Requirement

MT Newswires

5 months ago

Neurosense Therapeutics Files for Resale of Up to 5.28 Million Shares

MT Newswires

5 months ago

NeuroSense Signs Term Sheet for Phase 3 PrimeC Trial in Amyotrophic Lateral Sclerosis

NeuroSense Therapeutics Enters Binding Term Sheet to Advance PrimeC for ALS

PR Newswire

5 months ago

NeuroSense Therapeutics Enters Binding Term Sheet to Advance PrimeC for ALS

NeuroSense Provides Business Update and Third Quarter 2024 Financial Results

PR Newswire

5 months ago

NeuroSense Provides Business Update and Third Quarter 2024 Financial Results

NeuroSense Receives Positive FDA Feedback on Phase 3 Study Design for PrimeC

PR Newswire

5 months ago

NeuroSense Receives Positive FDA Feedback on Phase 3 Study Design for PrimeC

MT Newswires

5 months ago

NeuroSense Therapeutics Files Prospectus for Secondary Stock Sale

NeuroSense Announces Completion of PARADIGM Study Highlighting PrimeC's Significant Efficacy and Survival Benefits in ALS

PR Newswire

5 months ago

NeuroSense Announces Completion of PARADIGM Study Highlighting PrimeC's Significant Efficacy and Survival Benefits in ALS

NeuroSense Therapeutics Announces $5 Million Private Placement at Premium to Market Price

PR Newswire

5 months ago

NeuroSense Therapeutics Announces $5 Million Private Placement at Premium to Market Price

NeuroSense Therapeutics to Participate in the 2024 International Symposium on ALS/MND

PR Newswire

6 months ago

NeuroSense Therapeutics to Participate in the 2024 International Symposium on ALS/MND

MT Newswires

7 months ago

Neurosense, FDA to Meet Nov. 6 to Discuss Design of Amyotrophic Lateral Sclerosis Treatment Trial; Shares Rise

NeuroSense Secures Key FDA Meeting to Advance its Phase 3 ALS Trial and NDA Submission

PR Newswire

7 months ago

NeuroSense Secures Key FDA Meeting to Advance its Phase 3 ALS Trial and NDA Submission

EXCLUSIVE: Nano-Cap NeuroSense Schedules FDA Meeting To Advance Lead Program And Marketing Application Submission

Benzinga

7 months ago

EXCLUSIVE: Nano-Cap NeuroSense Schedules FDA Meeting To Advance Lead Program And Marketing Application Submission

New Analysis Shows PrimeC Significantly Improves Key miRNAs in ALS Patients

PR Newswire

7 months ago

New Analysis Shows PrimeC Significantly Improves Key miRNAs in ALS Patients

NeuroSense Advances Plans for Early Commercialization of Groundbreaking ALS Treatment in Canada, Provides Further Updates

PR Newswire

7 months ago

NeuroSense Advances Plans for Early Commercialization of Groundbreaking ALS Treatment in Canada, Provides Further Updates

MT Newswires

7 months ago

NeuroSense Therapeutics Seeking Early Regulatory Approval for Prospective ALS Treatment in Canada

NeuroSense Therapeutics Plans to File for Early Commercialization of ALS Treatment in Canada

PR Newswire

7 months ago

NeuroSense Therapeutics Plans to File for Early Commercialization of ALS Treatment in Canada

NeuroSense Therapeutics Announces Acceptance of Two PrimeC Abstracts at the 2024 NEALS Annual Meeting

PR Newswire

7 months ago

NeuroSense Therapeutics Announces Acceptance of Two PrimeC Abstracts at the 2024 NEALS Annual Meeting

NeuroSense Therapeutics Granted Key U.S. Patent for Novel PrimeC Formulation, its Lead Asset for ALS and Alzheimer's

PR Newswire

8 months ago

NeuroSense Therapeutics Granted Key U.S. Patent for Novel PrimeC Formulation, its Lead Asset for ALS and Alzheimer's

NeuroSense Regains Compliance with NASDAQ Minimum Bid Price Rule

PR Newswire

8 months ago

NeuroSense Regains Compliance with NASDAQ Minimum Bid Price Rule

NeuroSense Therapeutics Announces Receipt of Nasdaq Minimum Bid Price Notification

PR Newswire

8 months ago

NeuroSense Therapeutics Announces Receipt of Nasdaq Minimum Bid Price Notification

EXCLUSIVE: NeuroSense Therapeutics In Advanced Talks With Several Multi-Billion-Dollar Pharma Companies To Partner Its Lead Drug

Benzinga

9 months ago

EXCLUSIVE: NeuroSense Therapeutics In Advanced Talks With Several Multi-Billion-Dollar Pharma Companies To Partner Its Lead Drug

NeuroSense Therapeutics Announces Private Placement with Senior Management Participation at Premium to Market Price

PR Newswire

9 months ago

NeuroSense Therapeutics Announces Private Placement with Senior Management Participation at Premium to Market Price

NeuroSense Therapeutics Announces Positive Biomarker Data from ALS Phase 2b Clinical Trial

PR Newswire

9 months ago

NeuroSense Therapeutics Announces Positive Biomarker Data from ALS Phase 2b Clinical Trial

NeuroSense's PARADIGM ALS Clinical Trial Demonstrates Up to 73% Improved Complication-Free Survival Following Statistically Significant Slowing of Disease Progression

PR Newswire

10 months ago

NeuroSense's PARADIGM ALS Clinical Trial Demonstrates Up to 73% Improved Complication-Free Survival Following Statistically Significant Slowing of Disease Progression

NeuroSense Demonstrates Statistically Significant Efficacy and Survival Benefits in People Living with ALS: The Promising Results from the 12-Month PARADIGM Study Highlight PrimeC's Potential as a Disease Modifying Drug

PR Newswire

10 months ago

NeuroSense Demonstrates Statistically Significant Efficacy and Survival Benefits in People Living with ALS: The Promising Results from the 12-Month PARADIGM Study Highlight PrimeC's Potential as a Disease Modifying Drug

NeuroSense Management Provides Corporate Update and First Quarter 2024 Financial Results

PR Newswire

a year ago

NeuroSense Management Provides Corporate Update and First Quarter 2024 Financial Results

MT Newswires

a year ago

NeuroSense Therapeutics Receives Delisting Notice From Nasdaq

NeuroSense Receives Delisting Notice from Nasdaq and Intends to Appeal

PR Newswire

a year ago

NeuroSense Receives Delisting Notice from Nasdaq and Intends to Appeal

Lotto 6/49 - $64 million up for grabs in the next draw!

CNW Group

a year ago

Lotto 6/49 - $64 million up for grabs in the next draw!

Returns On Capital At B&S Group (AMS:BSGR) Paint A Concerning Picture

Simply Wall St.

a year ago

Returns On Capital At B&S Group (AMS:BSGR) Paint A Concerning Picture

Seoul says it will resume loudspeaker propaganda against North

AFP

a year ago

Seoul says it will resume loudspeaker propaganda against North

It Might Not Be A Great Idea To Buy PATRIZIA SE (ETR:PAT) For Its Next Dividend

Simply Wall St.

a year ago

It Might Not Be A Great Idea To Buy PATRIZIA SE (ETR:PAT) For Its Next Dividend

OUTsurance Group Insiders Placed Bullish Bets Worth R25.5m

Simply Wall St.

a year ago

OUTsurance Group Insiders Placed Bullish Bets Worth R25.5m

Fed Meeting, Inflation Report, Apple’s WWDC, Broadcom Earnings, and More to Watch This Week

Barrons.com

a year ago

Fed Meeting, Inflation Report, Apple’s WWDC, Broadcom Earnings, and More to Watch This Week

Just Three Days Till BREMER LAGERHAUS-GESELLSCHAFT -Aktiengesellschaft von 1877- (FRA:BLH) Will Be Trading Ex-Dividend

Simply Wall St.

a year ago

Just Three Days Till BREMER LAGERHAUS-GESELLSCHAFT -Aktiengesellschaft von 1877- (FRA:BLH) Will Be Trading Ex-Dividend

An Intrinsic Calculation For ORIOR AG (VTX:ORON) Suggests It's 35% Undervalued

Simply Wall St.

a year ago

An Intrinsic Calculation For ORIOR AG (VTX:ORON) Suggests It's 35% Undervalued

NeuroSense Vice President of R&D Shiran Zimri, Ph.D. to Participate in the 3rd Annual ALS Drug Development Summit

PR Newswire

a year ago

NeuroSense Vice President of R&D Shiran Zimri, Ph.D. to Participate in the 3rd Annual ALS Drug Development Summit

MT Newswires

a year ago

NeuroSense Partners with PhaseV for ALS Treatment Trial -- Shares Up

NeuroSense Partners with PhaseV to Optimize Upcoming ALS Phase 3 Trial Using Advanced Causal Machine Learning

PR Newswire

a year ago

NeuroSense Partners with PhaseV to Optimize Upcoming ALS Phase 3 Trial Using Advanced Causal Machine Learning

NeuroSense Announces New Positive Data Analysis from PARADIGM Clinical Trial Demonstrating Statistically Significant Slowing of Disease Progression in High-Risk ALS Patients

PR Newswire

a year ago

NeuroSense Announces New Positive Data Analysis from PARADIGM Clinical Trial Demonstrating Statistically Significant Slowing of Disease Progression in High-Risk ALS Patients

NeuroSense Announces First Quarter 2024 Business Update

PR Newswire

a year ago

NeuroSense Announces First Quarter 2024 Business Update

NeuroSense and Genetika+ Initiate Precision Medicine Collaboration Beginning with Ongoing Phase 2 Clinical Trial in Alzheimer's Disease

PR Newswire

a year ago

NeuroSense and Genetika+ Initiate Precision Medicine Collaboration Beginning with Ongoing Phase 2 Clinical Trial in Alzheimer's Disease

NeuroSense Presents Positive Data Validating Phase 2b Topline Readout During Emerging Science Presentation at the American Academy of Neurology Annual Meeting

PR Newswire

a year ago

NeuroSense Presents Positive Data Validating Phase 2b Topline Readout During Emerging Science Presentation at the American Academy of Neurology Annual Meeting

NeuroSense to Present PARADIGM Data at the American Academy of Neurology Annual Meeting April 16, 2024

PR Newswire

a year ago

NeuroSense to Present PARADIGM Data at the American Academy of Neurology Annual Meeting April 16, 2024

NeuroSense Announces Pricing of $4.5 Million Registered Direct Offering and Concurrent Private Placement

PR Newswire

a year ago

NeuroSense Announces Pricing of $4.5 Million Registered Direct Offering and Concurrent Private Placement

NeuroSense Collaborates with Lonza to Identify Exosome-based Biomarkers, in order to Advance Neurodegenerative Disease Treatments and Diagnostics

PR Newswire

a year ago

NeuroSense Collaborates with Lonza to Identify Exosome-based Biomarkers, in order to Advance Neurodegenerative Disease Treatments and Diagnostics

NeuroSense Announces Year End 2023 Financial Results and Provides Business Update

PR Newswire

a year ago

NeuroSense Announces Year End 2023 Financial Results and Provides Business Update

NeuroSense Reports Additional Positive Results from its ALS Phase 2b PARADIGM Trial

PR Newswire

a year ago

NeuroSense Reports Additional Positive Results from its ALS Phase 2b PARADIGM Trial

NeuroSense Regains Compliance with NASDAQ Minimum Bid Price Rule

PR Newswire

a year ago

NeuroSense Regains Compliance with NASDAQ Minimum Bid Price Rule

SR BANCORP, INC. ANNOUNCES QUARTERLY FINANCIAL RESULTS

PR Newswire

a year ago

SR BANCORP, INC. ANNOUNCES QUARTERLY FINANCIAL RESULTS

NeuroSense’s (NASDAQ:NRSN) ALS Drug Candidate Shows Promise In Recent Phase 2b Trial; More Milestones To Come In 2024

ACCESSWIRE

a year ago

NeuroSense’s (NASDAQ:NRSN) ALS Drug Candidate Shows Promise In Recent Phase 2b Trial; More Milestones To Come In 2024

Edgio Names BDO as Independent Auditor

Business Wire

a year ago

Edgio Names BDO as Independent Auditor

11 Hyper-Growth Stocks Billionaires Are Loading Up On

Insider Monkey

a year ago

11 Hyper-Growth Stocks Billionaires Are Loading Up On

Immix Biopharma Statement On January 2024 FDA Labeling Change Notification For Approved CAR-T Products

GlobeNewswire

a year ago

Immix Biopharma Statement On January 2024 FDA Labeling Change Notification For Approved CAR-T Products

Sphere 3D Announces Agreement with Core Scientific

Newsfile

a year ago

Sphere 3D Announces Agreement with Core Scientific

GlobeNewswire

a year ago

GYRODYNE ANNOUNCES RECORD DATE FOR PROPOSED RIGHTS OFFERING

3 Stocks With the Best Shot to 10X by 2025

InvestorPlace

a year ago

3 Stocks With the Best Shot to 10X by 2025

Glen Burnie Bancorp's (NASDAQ:GLBZ) Dividend Will Be $0.10

Simply Wall St.

a year ago

Glen Burnie Bancorp's (NASDAQ:GLBZ) Dividend Will Be $0.10

NeuroSense Recaps Positive 2023 Achievements Including Statistically Significant Slowing of Disease Progression in Phase 2b ALS Trial of PrimeC and Highlights Anticipated 2024 Catalysts

PR Newswire

a year ago

NeuroSense Recaps Positive 2023 Achievements Including Statistically Significant Slowing of Disease Progression in Phase 2b ALS Trial of PrimeC and Highlights Anticipated 2024 Catalysts

Business Wire

a year ago

Owlet Transforms Infant Care with the Launch of Two FDA-Cleared Devices – Dream Sock® and BabySat™

Tuttle Capital Management Launches 2x Inverse Regional Bank ETF

GlobeNewswire

a year ago

Tuttle Capital Management Launches 2x Inverse Regional Bank ETF

AppTech Payments Corp. to Attend Consumer Electronics Show in Las Vegas January 9-12, 2024

GlobeNewswire

a year ago

AppTech Payments Corp. to Attend Consumer Electronics Show in Las Vegas January 9-12, 2024

Psychemedics Corporation Announces Relocation of Headquarters to Dallas, Texas

GlobeNewswire

a year ago

Psychemedics Corporation Announces Relocation of Headquarters to Dallas, Texas

Li-Cycle Receives Continued Listing Standard Notice from NYSE

Business Wire

a year ago

Li-Cycle Receives Continued Listing Standard Notice from NYSE

Davis Commodities Limited Announces First Half of Fiscal Year 2023 Unaudited Financial Results

GlobeNewswire

a year ago

Davis Commodities Limited Announces First Half of Fiscal Year 2023 Unaudited Financial Results

NeuroSense Announces Receipt of Nasdaq Notice Regarding Minimum Stockholders' Equity Requirement

PR Newswire

a year ago

NeuroSense Announces Receipt of Nasdaq Notice Regarding Minimum Stockholders' Equity Requirement

Can Mixed Fundamentals Have A Negative Impact on AstroNova, Inc. (NASDAQ:ALOT) Current Share Price Momentum?

Simply Wall St.

a year ago

Can Mixed Fundamentals Have A Negative Impact on AstroNova, Inc. (NASDAQ:ALOT) Current Share Price Momentum?

We Think VirnetX Holding (NYSE:VHC) Needs To Drive Business Growth Carefully

Simply Wall St.

a year ago

We Think VirnetX Holding (NYSE:VHC) Needs To Drive Business Growth Carefully

NeuroSense Reports New Data: Statistically Significant Clinical Efficacy in Phase 2b ALS Trial

PR Newswire

a year ago

NeuroSense Reports New Data: Statistically Significant Clinical Efficacy in Phase 2b ALS Trial

santec Leverages Rimini Consult™ to Comprehensively Restructure its SAP Systems in Support of Major Corporate Restructuring

Business Wire

a year ago

santec Leverages Rimini Consult™ to Comprehensively Restructure its SAP Systems in Support of Major Corporate Restructuring

Many Still Looking Away From OceanPal Inc. (NASDAQ:OP)

Simply Wall St.

a year ago

Many Still Looking Away From OceanPal Inc. (NASDAQ:OP)

Li-Cycle Comments on Process to Evaluate Financing and Strategic Alternatives

Business Wire

a year ago

Li-Cycle Comments on Process to Evaluate Financing and Strategic Alternatives

We're A Little Worried About NeuroSense Therapeutics' (NASDAQ:NRSN) Cash Burn Rate

Simply Wall St.

a year ago

We're A Little Worried About NeuroSense Therapeutics' (NASDAQ:NRSN) Cash Burn Rate

NeuroSense's Phase 2b ALS Trial Achieves Primary Safety and Tolerability & Secondary Clinical Efficacy Endpoints

PR Newswire

a year ago

NeuroSense's Phase 2b ALS Trial Achieves Primary Safety and Tolerability & Secondary Clinical Efficacy Endpoints

NeuroSense to Report Phase 2b ALS Topline Primary Safety and Tolerability & Secondary Clinical Efficacy Endpoints on December 5, 2023

PR Newswire

a year ago

NeuroSense to Report Phase 2b ALS Topline Primary Safety and Tolerability & Secondary Clinical Efficacy Endpoints on December 5, 2023

Despite Fast-paced Momentum, Owlet, Inc. (OWLT) Is Still a Bargain Stock

Zacks

a year ago

Despite Fast-paced Momentum, Owlet, Inc. (OWLT) Is Still a Bargain Stock

NeuroSense Announces Third Quarter 2023 Financial Results and Provides Business Update

PR Newswire

a year ago

NeuroSense Announces Third Quarter 2023 Financial Results and Provides Business Update

Insider Spends US$59k Buying More Shares In Crown Crafts

Simply Wall St.

a year ago

Insider Spends US$59k Buying More Shares In Crown Crafts

President of Epsilon Energy Picks Up 13% More Stock

Simply Wall St.

a year ago

President of Epsilon Energy Picks Up 13% More Stock

Alarum: NetNut Announces Grant of a United States Patent

GlobeNewswire

a year ago

Alarum: NetNut Announces Grant of a United States Patent

The Glimpse Group Reports Q1 Fiscal Year 2024 Financial Results

ACCESSWIRE

2 years ago

The Glimpse Group Reports Q1 Fiscal Year 2024 Financial Results

Nortech Systems Incorporated (NASDAQ:NSYS) Q3 2023 Earnings Call Transcript

Insider Monkey

2 years ago

Nortech Systems Incorporated (NASDAQ:NSYS) Q3 2023 Earnings Call Transcript

PR Newswire

2 years ago

Willamette Valley Vineyards Announces Annual Cash Dividend for Series A Redeemable Preferred Stock

BGSF, Inc. Presenting at the 15th Annual Southwest IDEAS Investor Conference on November 15th in Dallas, TX

Business Wire

2 years ago

BGSF, Inc. Presenting at the 15th Annual Southwest IDEAS Investor Conference on November 15th in Dallas, TX

Zacks Small Cap Research

2 years ago

DYAI: Third Quarter Update

Viracta Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update

GlobeNewswire

2 years ago

Viracta Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update

Associated Press Finance

2 years ago

Priority Technology: Q3 Earnings Snapshot

Business Wire

2 years ago

Priority Technology Holdings, Inc. Announces Third Quarter 2023 Financial Results

NEW PACIFIC REPORTS FINANCIAL RESULTS FOR THE THREE MONTH ENDED SEPTEMBER 30, 2023

CNW Group

2 years ago

NEW PACIFIC REPORTS FINANCIAL RESULTS FOR THE THREE MONTH ENDED SEPTEMBER 30, 2023

Lumos Pharma Reports Third Quarter 2023 Financial Results and Clinical Development Updates

GlobeNewswire

2 years ago

Lumos Pharma Reports Third Quarter 2023 Financial Results and Clinical Development Updates

Share on Social Networks: